Fully Funded Growth Strategy Fly Flyte, Inc. (“Flyte”), a newly acquired subsidiary of VTAK, is now positioned to execute its expansion strategy with a fully funded growth plan supported by its parent ...

The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Praxis, or following a bona fide period of non-employment, as an ...

FORT MILL, SC / ACCESSWIRE / February 22, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a US-based medical device company focused on novel electrophysiology products, announced ...

Catheter Precision (VTAK) stock jumped 60% after revealing an $11.55M deal to purchase Fly Flyte and Ponderosa, expanding into aviation infrastructure.

This data was produced from a multi-center study that enrolled 125 patients. The data demonstrates that VIVO was over 94% accurate, assisted physicians in determining workflow when used pre-procedure, ...

Catheter Precision announced its audit opinion raised concerns about ongoing financial stability, as detailed in its recent 10-K report. Catheter Precision, Inc. has announced that its 2024 annual ...

FORT MILL, SC / ACCESSWIRE / April 24, 2024 / Catheter Precision, Inc. (NYSE American:VTAK) ($VTAK), a leading MedTech company specializing in innovative products for ...

Praxis Precision Medicines, Inc. ( PRAX) TD Cowen 46th Annual Health Care Conference March 2, 2026 11:50 AM EST ...

BOSTON, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...